Fig. 1From: Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fearsSchematic representation of therapeutic targets of mesenchymal stem cells (MSCs) in doxorubicin cardiomyopathy and tumor progression. LVEF, left ventricular ejection fractionBack to article page